Adverse events frequency caused by nivolumab and ipilimumab combination therapy: meta-analysis
Not Applicable
- Conditions
- cancers
- Registration Number
- JPRN-UMIN000044090
- Lead Sponsor
- Yokohama City University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 4677
Inclusion Criteria
Not provided
Exclusion Criteria
None
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Per-person frequencies of any AE (any grade, Grade 3 or higher(G3-)), serious AE (any grade, Grade 3 or higher), AE discontinuation (any grade, Grade 3 or higher), treatment-related death.
- Secondary Outcome Measures
Name Time Method